Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Homoharringtonine in AML
NCT04248595Phase 2Unknown
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine and homoharringtonine in acute myeloid leukemia (AML). Status: unknown.
02
Drugs
azacitidinehomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04248595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248595.